Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alzi Stop ODF is an orally dissolving film (ODF) formulation of the second-generation antihistamine cetirizine, developed by C.L. Pharm. It functions as a potent and selective antagonist of the peripheral histamine H1 receptor. By competing with free histamine for binding sites on effector cells, it prevents the typical allergic symptoms mediated by histamine release, such as vasodilation, increased capillary permeability, and sensory nerve stimulation. This formulation is specifically designed to dissolve rapidly in the mouth without the need for water, providing a convenient delivery method for the treatment of allergic rhinitis and chronic idiopathic urticaria. The ODF technology, a specialty of C.L. Pharm, aims to improve patient compliance, particularly for individuals with difficulty swallowing tablets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alzi Stop ODF (cetirizine).